Release Date: June 3, 2022
Expiration Date: June 2, 2023
Format: Video presentations with Q&A session

Target Audience

The target audience is adult and pediatric physicians and physician's assistants, nurse practitioners, fellows, dietitians and nutritionists, researchers, and patients.

Purpose

The purpose of this series is to increase the knowledge base of participants in the pathophysiology, clinical presentation, diagnosis, and management of celiac disease to make them aware of the potential increase of morbidity and mortality and to educate about the nature of a gluten-free diet. 

Educational Objectives

At the conclusion of this activity, participants will be better able to:

1. Evaluate the role of and use of serology in diagnosis of celiac disease
2. Discuss the different modalities utilized in making the diagnosis of celiac disease
3. Identify common presentations of celiac disease in the pediatric age group
4. Manage patients already on a gluten-free diet and patients' needs to clarify a diagnosis of celiac disease

Accreditation Statement

The Columbia University Vagelos College of Physicians and Surgeons is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statements

The Columbia University Vagelos College of Physicians and Surgeons designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Commission on Dietetic Registration has approved this activity for 2 CPEUs.

Agenda

Diagnosis of Celiac Disease in the Pediatric Age Group
Jaqueline Jossen, MD
Assistant Professor of Pediatrics, Celiac Disease Center at Columbia University, USA

Clinical Presentation of Adult Celiac Disease and the Role of Biopsies
Peter HR Green, MD
Phyllis & Ivan Seidenberg Professor of Medicine and Director, Celiac Disease Center at Columbia University, USA

Role of Serological Testing and Diagnosis in High-risk Groups.  Population Screening?
Knut Lundin, MD, PhD
Professor, Consultant, University of Oslo, Norway

Case Presentation/Q&A
 

Disclosures

All those involved with the planning and delivery of this education will disclose all financial relationships in the past 24 months with ineligible companies. An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. For each financial relationship, disclosure will include the name of the ineligible company and the nature of the financial relationship(s).

None of the planners/faculty for this educational activity have relevant financial relationships to disclose.

Acknowledgment

Supported by an educational grant from Takeda Development Center Americas, Inc.

Technical Requirements

This activity is best experienced using the most current browser (or one back) of Firefox, Chrome, Safari, Internet Explorer, or Microsoft Edge. For all activities featuring audio, you must have a sound card and speakers. To view graphic images and references that appear in separate "pop-up" windows, you must have JavaScript and session cookies enabled on your computer. Adobe Acrobat Reader may be required for certain activities.

Select the Continue button below to begin. You may return later if you are unable to complete the activity at this time.